Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07021209
PHASE1

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

Sponsor: Grit Biotechnology

View on ClinicalTrials.gov

Summary

This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.

Official title: A Single-arm, Open-label, Phase I Clinical Study of GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-01-14

Completion Date

2028-01-13

Last Updated

2025-09-15

Healthy Volunteers

No

Interventions

BIOLOGICAL

GT719 Injection

GT719 Injection

Locations (1)

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China